ANALYSIS OF CALRETICULIN (CALR) MUTATION IN MYELOFIBROSIS PATIENTS IN KHYBER PAKHTUNKHWA
DOI:
https://doi.org/10.52764/jms.22.30.1.1Keywords:
JAK2, Calreticulin, Myelofibrosi, Peshawar, Khyber PakhtunkhwaAbstract
Objective: To analyze the prevalence of CALR and JAK2 mutation co-occurrence in MF patients in KPK.
Methods: This cross-sectional study included MF patients (n = 50) enrolled in the Hematology/Oncology department of Hayatabad Medical Complex (HMC), IRNUM (Institute of Radiotherapy and Nuclear Medicine), Peshawar and Blood Diseases Clinic, Peshawar. Non-probability convenience sampling technique was used. All Patients with JAK2 V617F positive and negative primary or secondary myelofibrosis were included. After taking blood samples, DNA was extracted manually and analysed for JAK2 mutations using conventional PCR. Sanger sequencing technique was implied to analyse the samples for CALR mutations. Data were recorded & analysed statistically.
Results: Among the 50 patients of myelofibrosis under study, 48(96%) were harboring JAK2 mutations while it was not present in 2 (4%) patients. The typical CALR mutations was not identified in the current study. However, 02 specific genetic variants were identified in 30 patients i.e., a single nucleotide polymorphism (c.1381 G > T) in the 3? UTR and a novel insertion-deletion variant (c. 1099 CTT > AC). Seven patients had the Indel frameshift variant (p.Leu 367 Thr Fx 63), whereas 23 had SNPs. In JAK-2 positive patients (n=28), 06 had the Indel variant, and 22 had the SNPs. Two patients were JAK2 negative, one with SNP and the other with a frameshift mutation.
Conclusion: Majority of the MF patients had a novel frameshift variant (p. Leu367Thr Fx63) (n = 07) and an SNP in the 3? UTR region (G > T) (n = 23) in CALR gene.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.
